Search

Your search keyword '"Arina J ten Cate-Hoek"' showing total 3 results
Start Over Author "Arina J ten Cate-Hoek" Journal thrombosis journal
3 results on '"Arina J ten Cate-Hoek"'

1. Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation

Author

Rick J. H. Wetzels, Arina J. ten Cate-Hoek, Yvonne M. C. Henskens, Simon Schalla, Anouk J. W. Gulpen, Rene van Oerle, Harry J.G.M. Crijns, Henri M. H. Spronk, Hugo ten Cate, Paul W.M. Verhezen, RS: CARIM - R1.04 - Clinical thrombosis and haemostasis, MUMC+: DA CDL Algemeen (9), MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), MUMC+: DA CDL Analytisch cluster 1K (9), Interne Geneeskunde, Biochemie, Cardiologie, RS: CARIM - R3.11 - Imaging, MUMC+: MA Med Staf Spec Cardiologie (9), RS: CARIM - R2.01 - Clinical atrial fibrillation, MUMC+: MA Cardiologie (9), MUMC+: MA Alg Interne Geneeskunde (9), and MUMC+: HVC Pieken Trombose (9)

Subjects
Routine coagulation tests, REVERSAL, Drug concentration (diltPT, 030204 cardiovascular system & hematology, Thrombin time, Dabigatran, 03 medical and health sciences, 0302 clinical medicine, Rivaroxaban, medicine, Coagulation testing, ASSAYS, Drug concentration (diltPT, antiXa activity), Prothrombin time, medicine.diagnostic_test, PLASMA, business.industry, ROTEM (R), GUIDANCE, lcsh:RC633-647.5, Research, aPTT, Pt, Atrial fibrillation, Hematology, lcsh:Diseases of the blood and blood-forming organs, medicine.disease, Tt, APIXABAN, Thromboelastography, LABORATORY ASSESSMENT, Clotting time, Anesthesia, antiXa activity), DIRECT ORAL ANTICOAGULANTS, business, ROTEM®, 030215 immunology, medicine.drug
Abstract

Background Traditional coagulation tests are included in emergency guidelines for management of patients on direct oral anticoagulants (DOACs) who experience acute bleeding or require surgery. We determined the ability of traditional coagulation tests and fast whole blood thromboelastography (ROTEM®) to screen for anticoagulation activity of dabigatran and rivaroxaban as low as 30 ng/mL. Methods One hundred eighty-four citrated blood samples (75 dabigatran, 109 rivaroxaban) were collected from patients with non-valvular atrial fibrillation (NVAF), to perform screening tests from different manufacturers, (diluted, D) PT, aPTT, TT and ROTEM®. The activity of DOACs was quantitatively determined by clot detection assays: Hemoclot DTT and DiXaI test (Biophen), on CS2100 (Siemens). The clotting time (CT) of INTEM and EXTEM ROTEM® (Werfen) were used as test parameters. Results Dabigatran, ≥ 30 ng/mL, was accurately detected by five coagulation tests: APTT Actin FSL (93%), PT Neoplastin (93%), APTT Cephascreen, Thromboclotin, and Thrombin (all 100%), but not by PT Innovin (49%). CT-EXTEM (91%) was sufficiently sensitive, but not CT-INTEM (52%). APTT Cephascreen and Thrombin showed good linearity (R2 = 0.71,R2 = 0.72). For the other tests linearity was moderate to poor. Rivaroxaban was accurately detected by PT Neoplastin (98%) and less so by APTT Cephascreen (85%). In addition, rivaroxaban was also accurately detected by CT-INTEM (96%). PT Neoplastin showed good linearity (R2 = 0.81), all other tests had moderate to poor linearity. Conclusion In patients with NVAF, the ability of routine coagulation tests to detect the presence of significant levels of DOACs is test and reagent dependent. CT-INTEM and CT-EXTEM may be fast whole blood alternatives. Trial registration The Institutional Review Board of the MUMC approved this study (December 2011, project number 114069).

Published
2018
Full Text
View/download PDF

2. Postoperative thromboembolic prophylaxis in joint replacement surgery: Guidelines and daily practice

Author

Arina J. ten Cate-Hoek and Karly Hamulyák

Subjects
medicine.medical_specialty, Pediatrics, Joint replacement, business.industry, lcsh:RC633-647.5, General surgery, medicine.medical_treatment, Alternative medicine, lcsh:Diseases of the blood and blood-forming organs, Hematology, medicine.disease, Thrombosis, Thromboembolic prophylaxis, Daily practice, Commentary, medicine, business, Angiology
Abstract

This is a commentary discussing the article published in Thrombosis Journal by Subramanian et al. [Thrombosis Journal 2012, 10:15].

Full Text
View/download PDF

3. Prevalence of venous obstructions in (recurrent) venous thromboembolism: a case-control study

Author

Pascale Notten, Rob H. W. Strijkers, Irwin Toonder, Hugo ten Cate, and Arina J. ten Cate-Hoek

Subjects
Venous thromboembolism, Deep vein thrombosis, Recurrence, Postthrombotic syndrome, Quality of life, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract Background The role of venous obstructions as a risk factor for recurrent venous thromboembolism has never been evaluated. This study aimed to determine whether there is a difference in prevalence of venous obstructions between patients with and without recurrent venous thromboembolism. Furthermore, its influence on the development of post-thrombotic syndrome and patient-reported quality of life was assessed. Methods This matched nested case-control study included 32 patients with recurrent venous thromboembolism (26 recurrent deep-vein thrombosis and 6 pulmonary embolism) from an existing prospective cohort of deep-vein thrombosis patients and compared them to 24 age and sex matched deep-vein thrombosis patients without recurrent venous thromboembolism. All participants received standard post-thrombotic management and underwent an additional extensive duplex ultrasonography. Post-thrombotic syndrome was assessed by the Villalta-scale and quality of life was measured using the SF36v2 and VEINES-QOL/Sym-questionnaires. Results Venous obstruction was found in 6 patients (18.8%) with recurrent venous thromboembolism compared to 5 patients (20.8%) without recurrent venous thromboembolism (Odds ratio 0.88, 95%CI 0.23–3.30, p = 1.000). After a median follow-up of 60.0 months (IQR 41.3–103.5) the mean Villalta-score was 5.55 ± 3.02 versus 5.26 ± 2.63 (p = 0.909) and post-thrombotic syndrome developed in 20 (62.5%) versus 14 (58.3%) patients, respectively (Odds ratio 1.19, 95%CI 0.40–3.51, p = 0.752). If venous obstruction was present, it was mainly located in the common iliac vein (n = 7, 63.6%). In patients with an objectified venous obstruction the mean Villalta-score was 5.11 ± 2.80 versus 5.49 ± 2.87 in patients without venous obstruction (p = 0.639). Post-thrombotic syndrome developed in 6 (54.5%) versus 28 (62.2%) patients, respectively (Odds ratio 1.37, 95%CI 0.36–5.20, p = 0.736). No significant differences were seen regarding patient-reported quality of life between either groups. Conclusions In this exploratory case-control study patients with recurrent venous thromboembolism did not have a higher prevalence of venous obstruction compared to patients without recurrent venous thromboembolism. The presence of recurrent venous thromboembolism or venous obstruction had no impact on the development of post-thrombotic syndrome or the patient-reported quality of life.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results